LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.

The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease. PLoS Biol (2017) 1.37

Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15

Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. Front Mol Neurosci (2014) 1.03

LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis. Exp Neurol (2014) 0.88

The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling. Cell Death Dis (2014) 0.86

The role of the LRRK2 gene in Parkinsonism. Mol Neurodegener (2014) 0.85

Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. Neurobiol Dis (2013) 0.83

A visual review of the interactome of LRRK2: Using deep-curated molecular interaction data to represent biology. Proteomics (2015) 0.82

Alpha-synuclein Toxicity in the Early Secretory Pathway: How It Drives Neurodegeneration in Parkinsons Disease. Front Neurosci (2015) 0.80

α-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities. Cell Mol Neurobiol (2016) 0.80

G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons. J Neurosci (2016) 0.80

Glycation potentiates neurodegeneration in models of Huntington's disease. Sci Rep (2016) 0.77

From the baker to the bedside: yeast models of Parkinson's disease. Microb Cell (2015) 0.75

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model. Mol Ther Nucleic Acids (2017) 0.75

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30

Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40

Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99

Diagnostic criteria for Parkinson disease. Arch Neurol (1999) 11.65

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98

Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem (2006) 4.06

Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15

Biochemical and pathological characterization of Lrrk2. Ann Neurol (2006) 3.14

The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci (2010) 3.14

Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet (1999) 2.53

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J (2010) 2.43

14-3-3 proteins in the nervous system. Nat Rev Neurosci (2003) 2.02

Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain (2008) 1.92

Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Mol Cell Proteomics (2008) 1.46

Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J (2009) 1.42

Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol (2000) 1.36

Mendelian forms of Parkinson's disease. Biochim Biophys Acta (2009) 1.33

Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun (2006) 1.32

The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet (2003) 1.30

Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun (2009) 1.20

Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Mol Cell Neurosci (2008) 1.18

LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol Appl Neurobiol (2007) 1.08

Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One (2011) 1.04

Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. Acta Neuropathol (2011) 1.03

Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J Med Genet (2007) 1.02

Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal (2010) 1.01

Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2. FEBS J (2008) 1.01

LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol Neurodegener (2006) 1.00

α-synuclein, LRRK2 and their interplay in Parkinson's disease. Future Neurol (2012) 0.97

alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice. Acta Neuropathol (2006) 0.96

Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS One (2010) 0.96

Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Mov Disord (2007) 0.95

14-3-3 binds to and mediates phosphorylation of microtubule-associated tau protein by Ser9-phosphorylated glycogen synthase kinase 3beta in the brain. J Biol Chem (2004) 0.93

Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiol Aging (2009) 0.92

LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study. Neuropathol Appl Neurobiol (2011) 0.91

Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? Mol Neurodegener (2011) 0.85

Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies. Neurodegener Dis (2008) 0.84

The role of phosphorylation in synucleinopathies: focus on Parkinson's disease. CNS Neurol Disord Drug Targets (2010) 0.83

[Pathology of familial Parkinson's disease]. Brain Nerve (2007) 0.80

Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem (2006) 4.06

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 3.90

pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol (2004) 3.04

Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science (2003) 2.89

Spider silk fibers spun from soluble recombinant silk produced in mammalian cells. Science (2002) 2.69

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol (2004) 2.63

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol (2005) 2.61

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol (2005) 2.40

Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16

Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol (2003) 2.09

Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation (2007) 1.88

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol (2005) 1.78

Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A (2006) 1.73

Prescribing of smoking cessation medication in England since the introduction of varenicline. Addiction (2011) 1.65

Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci (2004) 1.63

Multifidus muscle changes and clinical effects of one-level posterior lumbar interbody fusion: minimally invasive procedure versus conventional open approach. Eur Spine J (2009) 1.62

AutismKB: an evidence-based knowledgebase of autism genetics. Nucleic Acids Res (2011) 1.59

Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output, internal relay, and striatal modulating nuclei. J Comp Neurol (2002) 1.58

Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc Natl Acad Sci U S A (2007) 1.54

Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54

Can data from primary care medical records be used to monitor national smoking prevalence? J Epidemiol Community Health (2011) 1.50

A piggyBac transposon-based genome-wide library of insertionally mutated Blm-deficient murine ES cells. Genome Res (2009) 1.48

Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci (2010) 1.46

P25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in multiple system atrophy. Acta Neuropathol (2006) 1.43

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol (2003) 1.41

Toll-like receptors expressed by dermal fibroblasts contribute to hypertrophic scarring. J Cell Physiol (2011) 1.36

A PiggyBac-based recessive screening method to identify pluripotency regulators. PLoS One (2011) 1.30

Bladder outlet obstruction: progression from inflammation to fibrosis. BJU Int (2010) 1.28

Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J Immunol (2003) 1.27

Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release (2005) 1.24

Variations in the neuropathology of familial Alzheimer's disease. Acta Neuropathol (2009) 1.22

Retracted Curcumin prevents and reverses murine cardiac hypertrophy. J Clin Invest (2008) 1.15

A homozygous mutant embryonic stem cell bank applicable for phenotype-driven genetic screening. Nat Methods (2011) 1.11

Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med (2005) 1.11

Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways. Free Radic Biol Med (2006) 1.10

A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol (2010) 1.10

The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol (2010) 1.09

Multichannel monolithic quartz crystal microbalance gas sensor array. Anal Chem (2009) 1.09

Loss of miR-29b following acute ischemic stroke contributes to neural cell death and infarct size. J Cereb Blood Flow Metab (2013) 1.08

p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol (2007) 1.08

Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci (2005) 1.06

Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J Virol (2002) 1.05

SIRT2 as a Therapeutic Target for Age-Related Disorders. Front Pharmacol (2012) 1.04

Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One (2011) 1.04

Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. Acta Neuropathol (2011) 1.03

c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum Mol Genet (2014) 1.03

A filovirus-unique region of Ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virions. J Virol (2008) 1.01

Visualization of cell-to-cell transmission of mutant huntingtin oligomers. PLoS Curr (2011) 1.01

Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci (2012) 1.01

The therapeutic efficacy of conjugated linoleic acid - paclitaxel on glioma in the rat. Biomaterials (2010) 1.00

Genome-wide analysis of acetivibrio cellulolyticus provides a blueprint of an elaborate cellulosome system. BMC Genomics (2012) 1.00

The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. EMBO J (2013) 0.99

Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci (2004) 0.98

The microRNA miR-199a-5p down-regulation switches on wound angiogenesis by derepressing the v-ets erythroblastosis virus E26 oncogene homolog 1-matrix metalloproteinase-1 pathway. J Biol Chem (2012) 0.97

Akt-signal integration is involved in the differentiation of embryonal carcinoma cells. PLoS One (2013) 0.97

Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin. BMC Biotechnol (2008) 0.97

Bayesian nonparametric dictionary learning for compressed sensing MRI. IEEE Trans Image Process (2014) 0.97

Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment. Autophagy (2014) 0.96

Sirtuins: common targets in aging and in neurodegeneration. Curr Drug Targets (2010) 0.96

Validation of The Health Improvement Network (THIN) primary care database for monitoring prescriptions for smoking cessation medications. Pharmacoepidemiol Drug Saf (2010) 0.96

The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats. J Drug Target (2010) 0.95

Unifying model for molecular determinants of the preselection Vβ repertoire. Proc Natl Acad Sci U S A (2013) 0.95

The potential role of microRNA-146 in Alzheimer's disease: biomarker or therapeutic target? Med Hypotheses (2011) 0.95

Nontraumatic acute paraplegia associated with cervical disk herniation. J Spinal Cord Med (2010) 0.95

Validation of the Chinese version of Addenbrooke's cognitive examination-revised for screening mild Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord (2013) 0.94

PKMζ is essential for spinal plasticity underlying the maintenance of persistent pain. Mol Pain (2011) 0.94

Annular alpha-synuclein species from purified multiple system atrophy inclusions. J Neurochem (2004) 0.93

Small bowel preparations for capsule endoscopy with mannitol and simethicone: a prospective, randomized, clinical trial. J Clin Gastroenterol (2011) 0.93

Effect of vagus nerve stimulation on thermal injury in rats. Burns (2009) 0.93

A20 attenuates vascular smooth muscle cell proliferation and migration through blocking PI3k/Akt singling in vitro and in vivo. J Biomed Sci (2007) 0.92

Dominantly-inherited adult-onset leukodystrophy with palatal tremor caused by a mutation in the glial fibrillary acidic protein gene. Mov Disord (2004) 0.92

Plasticity of interstitial cells of cajal: a study in the small intestine of adult Guinea pigs. Anat Rec (Hoboken) (2009) 0.92

A20 inhibits oxidized low-density lipoprotein-induced apoptosis through negative Fas/Fas ligand-dependent activation of caspase-8 and mitochondrial pathways in murine RAW264.7 macrophages. J Cell Physiol (2006) 0.91

Comparison of paraspinal muscle injury in one-level lumbar posterior inter-body fusion: modified minimally invasive and traditional open approaches. Orthop Surg (2010) 0.90

Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Biomaterials (2012) 0.90

Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm Res (2005) 0.90

Medical potential of plants used by the Q'eqchi Maya of Livingston, Guatemala for the treatment of women's health complaints. J Ethnopharmacol (2007) 0.90

Simple is good: yeast models of neurodegeneration. FEMS Yeast Res (2010) 0.89

Hemoglobinopathy: molecular epidemiological characteristics and health effects on Hakka people in the Meizhou region, southern China. PLoS One (2013) 0.89

KATP channel: relation with cell metabolism and role in the cardiovascular system. Int J Biochem Cell Biol (2005) 0.89

Regulation of microsomal triglyceride transfer protein by apolipoprotein A-IV in newborn swine intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2010) 0.88

Surface acoustic wave nebulization facilitating lipid mass spectrometric analysis. Anal Chem (2012) 0.88

Incorporation of pol into human immunodeficiency virus type 1 Gag virus-like particles occurs independently of the upstream Gag domain in Gag-pol. J Virol (2004) 0.88

alpha-Synuclein filaments bind the transcriptional regulator HMGB-1. Neuroreport (2004) 0.87

Standardized ginger (Zingiber officinale) extract reduces bacterial load and suppresses acute and chronic inflammation in Mongolian gerbils infected with cagAHelicobacter pylori. Pharm Biol (2009) 0.87

Population pharmacokinetics of intravenous bolus etomidate in children over 6 months of age. Paediatr Anaesth (2011) 0.87

History, present, and progress of frontotemporal dementia in china: a systematic review. Int J Alzheimers Dis (2012) 0.87

Endometrioid carcinoma of the fallopian tube resembling an adnexal tumor of probable wolffian origin: a case of report and review of the literature. Pathol Res Pract (2009) 0.87

DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitro. Mov Disord (2013) 0.86

Spatially complex neighboring relationships among grassland plant species as an effective mechanism of defense against herbivory. Oecologia (2010) 0.86

PLK2 modulates α-synuclein aggregation in yeast and mammalian cells. Mol Neurobiol (2013) 0.86

Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains. Biochem J (2011) 0.86

The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel. Biomaterials (2011) 0.86

VISA--a pass to innate immunity. Int J Biochem Cell Biol (2006) 0.85

Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy. Mol Neurobiol (2013) 0.85

Susceptibility to neonicotinoids and risk of resistance development in the brown planthopper, Nilaparvata lugens (Stål) (Homoptera: Delphacidae). Pest Manag Sci (2008) 0.85

α-Synuclein modifies huntingtin aggregation in living cells. FEBS Lett (2011) 0.85

Cyclin A1 is a transcriptional target of PITX2 and overexpressed in papillary thyroid carcinoma. Mol Cell Biochem (2013) 0.85

NSF, Unc-18-1, dynamin-1 and HSP90 are inclusion body components in neuronal intranuclear inclusion disease identified by anti-SUMO-1-immunocapture. Acta Neuropathol (2008) 0.84